Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication
Authors:
Open Access
- 2 December 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 129 (6) , 1503-1510
Abstract
Oncolytic herpes simplex virus (HSV) is currently in phase III clinical trials for development as a novel therapeutic agent against a broad range of human tumors. Although results have been promising, clinical outcome is likely to be compromised by intrinsic and acquired resistance to HSV replication, leading us to test agents that may overcome this obstacle. We found that, despite showing no effect on HSV replication in tumor cells fully permissive to the virus growth, the mTOR inhibitor rapamycin markedly increased the yield and dissemination of oncolytic HSVs in semipermissive tumor cells. Similar results were obtained in tumor‐bearing mice. Co‐administration of rapamycin with an HSV‐derived oncolytic virus either blocked or reversed the growth of tumor xenografts established from semipermissive human tumor cells, while use of either agent alone produced only transient inhibitory effect. Together, our results suggest that rapamycin could be used to potentiate the activity of oncolytic HSVs against difficult‐to‐treat human tumors or perhaps to prevent the emergence of resistant tumor cells during virotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus ReplicationJournal of Virology, 2010
- Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN productionProceedings of the National Academy of Sciences, 2010
- RAPping production of type I interferon in pDCs through mTORNature Immunology, 2008
- Coadministration of a Herpes Simplex Virus-2–Based Oncolytic Virus and Cyclophosphamide Produces a Synergistic Antitumor Effect and Enhances Tumor-Specific Immune ResponsesCancer Research, 2007
- Viruses as anticancer drugsTrends in Pharmacological Sciences, 2007
- Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor CellsJournal of Virology, 2007
- Serial Passage through Human Glioma Xenografts Selects for a Δγ 1 34.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain TumorsJournal of Virology, 2006
- A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic VirusMolecular Therapy, 2006
- Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancerThe Prostate, 2004
- Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumorsGene Therapy, 2003